Trends in Anti-Epileptic Drug Development by Lennart Gram

Get full text

AROMATHERAPY: THE ANCIENT AND MODERN APPROACHTOWARDS DRUG DEVELOPMENT

“…Historically the use of aromatherapy is known in the field of clinical sciences by using herbal essential oils in different techniques.Nowadays this field of therapy is used in modern drug development and curing various diseases by essential aromatic oil. …”
Get full text

The PPAR Ω Pocket: Renewed Opportunities for Drug Development by Åsmund Kaupang, Trond Vidar Hansen

Get full text

Stapled peptides: targeting protein-protein interactions in drug development by Qian Zhang, Ziyang Wang, Xiaohan Mei, Quan Chen, Chunqiu Zhang

Get full text

The Nicotinic Acetylcholine Receptor as a Target for Antidepressant Drug Development by Noah S. Philip, Linda L. Carpenter, Audrey R. Tyrka, Lawrence H. Price

“…An important new area of antidepressant drug development involves targeting the nicotinic acetylcholine receptor (nAChR). …”
Get full text

Editorial: Latest findings on Leishmania parasites for better vaccine design and drug development by Negar Seyed, Tahereh Taheri, Farhat Afrin, Hamidreza Majidiani, Hamidreza Majidiani

Get full text

Combating antibiotic resistance: mechanisms, challenges, and innovative approaches in antibacterial drug development by Aiswarya M. Rajesh, Shraddha Subhash Pawar, Kruthi Doriya, Rambabu Dandela

Subjects: Get full text

Phaleria macrocarpa (Scheff.) Boerl. in Ethnopharmacology: Pharmacognosy, Safety, and Drug Development Perspectives by Anandarajagopal Kalusalingam, Kamaliah Kamal, Abdullah Khan, Bama Menon, Ching Siang Tan, Venkateshan Narayanan, Sattanathan Kumar, Khang Wen Goh, Kah Seng Lee, Jactty Chew, Long Chiau Ming

Get full text

Identification of new ClpC1-NTD binders for Mycobacterium tuberculosis drug development by Katharina Weinhäupl, Louis Meuret, Sandy Desrat, Fanny Roussy, Nelly Morellet, Sandra Beaupierre, Catherine Guillou, Carine van Heijenoort, Olga Abian, Sonia Vega, Ian Wolf, Tatos Akopian, Olga Krandor, Eric Rubin, Adrian Velazquez-Campoy, Diego Gauto, Hugo Fraga

Get full text

The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development by Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial

Get full text

Vaginal Tritrichomonas foetus infection in mice as an in vivo model for drug development against Trichomonas vaginalis. by Noelle M Nieskens, Yukiko Miyamoto, Brianna M Hurysz, Anthony J O'Donoghue, Lars Eckmann

“…Critical for antimicrobial drug development is the demonstration of in vivo efficacy. …”
Get full text

Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials by Matt Vassar, Vinay Prasad, Ryan McIntire, Alyson Haslam, Brody Dennis, Chance Bratten, Griffin K Hughes, Andriana M Peña, Chase Ladd, Brooke Gardner, William Nowlin, Reagan Livingston, Jordan Tuia

Get full text

Integrating Model‐Informed Drug Development With AI: A Synergistic Approach to Accelerating Pharmaceutical Innovation by Karthik Raman, Rukmini Kumar, Cynthia J. Musante, Subha Madhavan

“…ABSTRACT The pharmaceutical industry constantly strives to improve drug development processes to reduce costs, increase efficiencies, and enhance therapeutic outcomes for patients. …”
Get full text

Accelerating TB regimen development: introducing FAST-TB by T. Devezin, C. Chisholm, F. Jones, K. Lacourciere, B. Laughon, L. Ramachandra, A. Vernon, L. Zhang, P. Kim, C. Lienhardt

Subjects: Get full text

Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development by Montserrat Carrasco-Triguero, Helen Davis, Yuda Zhu, Daniel Coleman, Denise Nazzal, Paul Vu, Surinder Kaur

“…During early stages of drug development for antibody-drug conjugates (ADCs), there is the added complication of the potential inclusion of several molecular variants in a study, differing in the linker and/or drug components. …”
Get full text

Harnessing the power of structure‐based design: A new lease on life for cardiovascular drug development with apelin receptor modulators by Junxia Zhang, Erdan Dong, Yan Zhang, Yan Zhang

Get full text

Salt Stress Enhanced Bioactivity of Quinoa Leaf Extracts: An In Vitro and In Silico Study of Acetylcholinesterase and Tyrosinase Inhibition for Sustainable Drug Development by Narmine Slimani, Soumaya Arraouadi, Hafedh Hajlaoui, Antonio Cid-Samamed, Mohamed Ali Borgi, Mejdi Snoussi

Get full text

Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity by Jaeseong Oh, Sojeong Yi, Namyi Gu, Dongseong Shin, Kyung-Sang Yu, Seo Hyun Yoon, Joo-Youn Cho, In-Jin Jang

Subjects: Get full text

The evolution of antifungal therapy: Traditional agents, current challenges and future perspectives by Cássia Milena de Souza, Bárbara Tavares Bezerra, Daniel Agreda Mellon, Haroldo Cesar de Oliveira

Subjects: Get full text

COVID‐19 in early 2023: Structure, replication mechanism, variants of SARS‐CoV‐2, diagnostic tests, and vaccine & drug development studies by Ilker Polatoğlu, Tulay Oncu‐Oner, Irem Dalman, Senanur Ozdogan

Get full text